Irving Weissman

Last updated
Irving Weissman
Born(1939-10-21)October 21, 1939
Great Falls, Montana
Alma mater
Scientific career
Institutions

Irving Lerner "Irv" Weissman (born Great Falls, Montana, October 21, 1939) [1] is a Professor of Pathology and Developmental Biology at Stanford University [2] where he is the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine along with Michael Longaker.

Contents

Weissman was raised in Great Falls, Montana and started his scientific career at the McLaughlin Research Institute there. He obtained his MD from Stanford University in 1965 after earning a BS from Montana State University in 1961. His research has since focused on hematopoietic stem cell biology.

Early life

Weissman was not an exceptionally good student in high school. [3] He started assisting with medical research in 1956, when he got a summer job at Montana Deaconess Hospital. He preferred the idea of caring for laboratory mice and assisting in the lab to washing cars or similar jobs that were available to teenaged boys in the area. He was inspired by the idea that he could think scientifically and respond to a questioning, Socratic method, rather than didactic lectures about scientific facts. He ran his first experiment there during his senior year in high school, to see whether he could repeat an experiment that had recently been published. He attributes his admission to college and medical school to the resulting publications, rather than to his less-than-perfect grades. [3]

Awards

His awards include election to the National Academy of Sciences in 1989, named California Scientist of the Year in 2002, [4] and elected to the American Philosophical Society in 2008. [5]

Research focus

He developed methods to identify stem cells, and has extensively researched stem cells and progenitor cells. [9] His research focus is "the phylogeny and developmental biology of the cells that make up the blood-forming and immune system." [2] Weissman is widely recognized as the "father of hematopoiesis" since he was the first to purify blood forming stem cells in both mice and humans. His laboratory purified stem cells from other mature cells, such as B cells, by observing the different lineage markers expressed by each immune cell type. So when the immune cells of mice reacted with fluorescently labeled antibodies specific to effector cells, the mature cells were differentiated from the newly forming stem cells. [10] His work has contributed to the understanding of how a single hematopoietic stem cell can give rise to specialized blood cells.

Weissman is also a leading expert in the field of cancer stem cell biology, where his work sheds light on the understanding of the pathogenesis of multiple human malignancies. He is also known for transgenic research in which human brain cells are grown in the brains of mice.

Related Research Articles

<span class="mw-page-title-main">Haematopoiesis</span> Formation of blood cellular components

Haematopoiesis is the formation of blood cellular components. All cellular blood components are derived from haematopoietic stem cells. In a healthy adult human, roughly ten billion to a hundred billion new blood cells are produced per day, in order to maintain steady state levels in the peripheral circulation.

The Stanford University School of Medicine is the medical school of Stanford University and is located in Stanford, California, United States. It traces its roots to the Medical Department of the University of the Pacific, founded in San Francisco in 1858. This medical institution, then called Cooper Medical College, was acquired by Stanford in 1908. The medical school moved to the Stanford campus near Palo Alto, California, in 1959.

Tak Wah Mak, is a Canadian medical researcher, geneticist, oncologist, and biochemist. He first became widely known for his discovery of the T-cell receptor in 1983 and pioneering work in the genetics of immunology. In 1995, Mak published a landmark paper on the discovery of the function of the immune checkpoint protein CTLA-4, thus opening the path for immunotherapy/checkpoint inhibitors as a means of cancer treatment. Mak is also the founder of Agios Pharmaceuticals, whose lead compound, IDHIFA®, was approved by the FDA for acute myeloid leukemia in August 2017, becoming the first drug specifically targeting cancer metabolism to be used for cancer treatment. He has worked in a variety of areas including biochemistry, immunology, and cancer genetics.

<span class="mw-page-title-main">John Edgar Dick</span> Canadian cancer researcher (born 1954)

John Edgar Dick is Canada Research Chair in Stem Cell Biology, Senior Scientist at the Princess Margaret Cancer Centre, University Health Network and Professor in the Department of Molecular Genetics at the University of Toronto in Canada. Dick is credited with first identifying cancer stem cells in certain types of human leukemia. His revolutionary findings highlighted the importance of understanding that not all cancer cells are the same and thus spawned a new direction in cancer research. Dick is also known for his demonstration of a blood stem cell's ability to replenish the blood system of a mouse, his development of a technique to enable an immune-deficient mouse to carry and produce human blood, and his creation of the world's first mouse with human leukemia.

<span class="mw-page-title-main">Klaus Rajewsky</span>

Klaus Rajewsky is a German immunologist, renowned for his work on B cells.

<span class="mw-page-title-main">Sean J. Morrison</span> Canadian-American cancer researcher

Sean J. Morrison is a Canadian-American stem cell biologist and cancer researcher. Morrison is the director of Children's Medical Center Research Institute at UT Southwestern (CRI), a nonprofit research institute established in 2011 as a joint venture between Children’s Health System of Texas and UT Southwestern Medical Center. With Morrison as founding director, CRI was established to perform transformative biomedical research at the interface of stem cell biology, cancer and metabolism to better understand the biological basis of disease. He is a Howard Hughes Medical Institute Investigator, has served as president of the International Society for Stem Cell Research, and is a member of the U.S. National Academy of Medicine, U.S. National Academy of Sciences and European Molecular Biology Organization.

<span class="mw-page-title-main">Robert Peter Gale</span> American physician and medical researcher

Robert Peter Gale is an American physician and medical researcher. He is known for research in leukemia and other bone marrow disorders.

<span class="mw-page-title-main">Lloyd J. Old</span> 20th-century American immunology researcher

Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.

Utpal Banerjee is a distinguished professor of the department of molecular, cell and developmental biology at UCLA. He obtained his Bachelor of Science degree in chemistry from St. Stephen's College, Delhi University, India and obtained his Master of Science degree in physical chemistry from the Indian Institute of Technology, Kanpur, India. In 1984, he obtained a PhD in chemistry from the California Institute of Technology where he was also a postdoctoral Fellow in the laboratory of Seymour Benzer from 1984-1988.

<span class="mw-page-title-main">Robert D. Schreiber</span> American immunologist

Robert D. Schreiber is an immunologist and currently is the Alumni Endowed Professor of Pathology and Immunology at Washington University School of Medicine. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work on the cancer immunoediting hypothesis has helped reveal that the immune system is not only capable of destroying cancers, but can also drive them into a dormant state that, in some cases, results in an improved state of malignancy.

<span class="mw-page-title-main">Joan Massagué</span> Spanish biologist

Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.

Marcel R.M. van den Brink is a Dutch oncologist and researcher known for his research in hematopoietic stem cell transplantation for cancer patients.

Amy J. Wagers is the Forst Family Professor of Stem Cell and Regenerative Biology at Harvard University and Harvard Medical School, an investigator in islet cell and regenerative biology at the Joslin Diabetes Center, and principal faculty of the Harvard Stem Cell Institute. She is co-chair of the Department of Stem Cells and Regenerative Biology at Harvard Medical School.

Owen Witte is an American physician-scientist at the University of California, Los Angeles. He is a University Professor of microbiology, immunology and molecular genetics in the David Geffen School of Medicine at UCLA, founding director emeritus of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and the UC Regents’ David Saxon Presidential Chair in developmental immunology (1989–present). Witte is also a Howard Hughes Medical Institute investigator (1986–2016) and a member of the President's Cancer Panel, the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Cancer Research Academy of the AACR. He serves on numerous editorial boards and scientific advisory boards for academic centers and biotechnology companies.

<span class="mw-page-title-main">Derrick Rossi</span> Canadian stem cell biologist

Derrick J. Rossi, is a Canadian stem cell biologist and entrepreneur. He is a co-founder of the pharmaceutical company Moderna.

Ann S. Tsukamoto Weissman is an Asian American stem cell researcher and inventor. In 1991, she co-patented a process that allowed the human stem cell to be isolated and demonstrated their potential in treating patients with metastatic breast cancer.

Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.

Laurence Zitvogel is a French physician-scientist specializing in oncology and immunology. Zitvogel is a clinical oncologist, a researcher in the Laboratory of Tumor Immunology and Immunotherapy, and a professor at Paris-Saclay University. She has studied the correlation between the immune system and the success of cancer treatments for over 30 years. Her primary research experience lies in exosomes, studying the biological impact of structural abnormalities on malignant neoplasms, and anti-tumor therapy. Through her work as a professor and researcher, Zitvogel discovered that chemotherapy could delay the growth of tumors in mouse models. Her team reported the first anticancer probiotic, Enterococcus hirae. As of 2020, she is researching an effective and inexpensive diagnostic test to predict dysbiosis and is investigating the promising lead on the role of gut microbiotes in anti-tumour immunotherapy.

Maria Grazia Roncarolo is an Italian pediatrician who is currently George D. Smith Professor in Stem Cell and Regenerative Medicine and Professor of Medicine at Stanford University. She is also the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine along with Irving Weissman and Michael Longaker and the Director for Center for Definitive and Curative Medicine at Stanford.

<span class="mw-page-title-main">Christa Muller-Sieburg</span> German-American Immunologist and Hematologist

Christa Edith Muller-Sieburg was a German-American immunologist and hematologist, whose work became central to the understanding of the clonal heterogeneity of hematopoietic stem cells (HSCs). Muller-Sieburg is known for her contributions to the purification of hematopoietic stem cells, the characterization of individual stem cell clones and her revision of the process of hematopoiesis.

References

  1. ↑ Weissman, Irving L., American Men and Women of Science, Eds. Pamela Kalte, Katherine Nemeh and Noah Schusterbauer, Vol. 7, 22nd Ed. Detroit: Gale, 2005, p552-553. Gale Document Number: CX3454833983. Retrieved November 8, 2010
  2. 1 2 "Faculty & Researcher Profiles - Irving Weissman". Stanford University Medical Center. Archived from the original on January 4, 2011. Retrieved August 27, 2011.
  3. 1 2 Weissman, Irving (2016-01-01). "How One Thing Led to Another". Annual Review of Immunology. 34 (1): 1–30. doi: 10.1146/annurev-immunol-032414-112003 . PMID   27168238.
  4. ↑ "Irving Weissman, M.D. 2002 California Scientist of the Year". Archived from the original on 2011-05-22. Retrieved 2008-06-09.
  5. ↑ "APS Member History". search.amphilsoc.org. Retrieved 2021-05-03.
  6. ↑ "Brupbacher Preis – Charles Rodolphe Brupbacher Stiftung". Archived from the original on 2018-10-23. Retrieved 2018-10-23.
  7. ↑ Albany Medical Center Prize
  8. ↑ "Annual Stibitz-Wilson Awards to honor 'visionaries at the nexus of medicine and technology'". Montana State University. Retrieved 2025-01-25.
  9. ↑ "Biography Format for Board of Trustees' Agenda: A brief introduction of Irving L. Weissman, M.D." Retrieved November 8, 2010
  10. ↑ Jones, Judith A. Owen, Jenni Punt, Sharon A. Stranford; with contributions by Patricia P. (2013). Kuby immunology (Seventh ed.). New York: W.H. Freeman. p. 31. ISBN   9781429219198.{{cite book}}: CS1 maint: multiple names: authors list (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.